255 related articles for article (PubMed ID: 35497636)
1. Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications.
Elmariah S; Chisolm S; Sciascia T; Kwatra SG
JAAD Int; 2022 Jun; 7():156-163. PubMed ID: 35497636
[TBL] [Abstract][Full Text] [Related]
2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus.
Mathur VS; Kumar J; Crawford PW; Hait H; Sciascia T;
Am J Nephrol; 2017; 46(6):450-458. PubMed ID: 29253847
[TBL] [Abstract][Full Text] [Related]
3. Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.
Inan S; Dun NJ; Cowan A
Molecules; 2021 Sep; 26(18):. PubMed ID: 34576988
[TBL] [Abstract][Full Text] [Related]
4. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
5. Effects of butorphanol on morphine-induced itch and analgesia in primates.
Lee H; Naughton NN; Woods JH; Ko MC
Anesthesiology; 2007 Sep; 107(3):478-85. PubMed ID: 17721251
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase.
Weisshaar E; Szepietowski JC; Bernhard JD; Hait H; Legat FJ; Nattkemper L; Reich A; Sadoghi B; Sciascia TR; Zeidler C; Yosipovitch G; Ständer S
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):453-461. PubMed ID: 34780095
[TBL] [Abstract][Full Text] [Related]
7. Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans.
Inan S; Cowan A
Handb Exp Pharmacol; 2022; 271():275-292. PubMed ID: 33296031
[TBL] [Abstract][Full Text] [Related]
8. Difelikefalin: A New κ-Opioid Receptor Agonist for the Treatment of Hemodialysis-Dependent Chronic Kidney Disease-Associated Pruritus.
Fugal J; Serpa SM
Ann Pharmacother; 2023 Apr; 57(4):480-488. PubMed ID: 35942600
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.
Morgenweck J; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():600-9. PubMed ID: 26318102
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus.
Yosipovitch G; Awad A; Spencer RH; Munera C; Menzaghi F
J Am Acad Dermatol; 2023 Aug; 89(2):261-268. PubMed ID: 37059302
[TBL] [Abstract][Full Text] [Related]
11. Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review.
Wala K; Szepietowski JC
Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015082
[TBL] [Abstract][Full Text] [Related]
12. Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus.
Düll MM; Wolf K; Vetter M; Dietrich P; Neurath MF; Kremer AE
Front Med (Lausanne); 2021; 8():641163. PubMed ID: 33937284
[No Abstract] [Full Text] [Related]
13. Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.
Inan S; Torres-Huerta A; Jensen LE; Dun NJ; Cowan A
Eur J Pharmacol; 2019 Dec; 864():172702. PubMed ID: 31568781
[TBL] [Abstract][Full Text] [Related]
14. Intravenous difelikefalin for the treatment of hemodialysis pruritus.
Mahmoud RH; Mahmoud O; Yosipovitch G
Expert Rev Clin Immunol; 2024; 20(1):31-37. PubMed ID: 37847514
[TBL] [Abstract][Full Text] [Related]
15. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.
Phan NQ; Lotts T; Antal A; Bernhard JD; Ständer S
Acta Derm Venereol; 2012 Sep; 92(5):555-60. PubMed ID: 22504709
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Opioid Pathway for Uremic Pruritus: A Systematic Review and Meta-analysis.
Jaiswal D; Uzans D; Hayden J; Kiberd BA; Tennankore KK
Can J Kidney Health Dis; 2016; 3():2054358116675345. PubMed ID: 28270926
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies.
Topf J; Wooldridge T; McCafferty K; Schömig M; Csiky B; Zwiech R; Wen W; Bhaduri S; Munera C; Lin R; Jebara A; Cirulli J; Menzaghi F
Kidney Med; 2022 Aug; 4(8):100512. PubMed ID: 36016762
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.
Kaski SW; White AN; Gross JD; Trexler KR; Wix K; Harland AA; Prisinzano TE; Aubé J; Kinsey SG; Kenakin T; Siderovski DP; Setola V
J Pharmacol Exp Ther; 2019 Nov; 371(2):487-499. PubMed ID: 31492823
[TBL] [Abstract][Full Text] [Related]
19. Kappa opioid agonists in the treatment of itch: just scratching the surface?
Beck TC; Wilson EM; Wilkes E; Lee LW; Norris R; Valdebran M
Itch (Phila); 2023; 8(4):. PubMed ID: 38099236
[TBL] [Abstract][Full Text] [Related]
20. Role of kappa-opioid and mu-opioid receptors in pruritus: Peripheral and central itch circuits.
Kim BS; Inan S; Ständer S; Sciascia T; Szepietowski JC; Yosipovitch G
Exp Dermatol; 2022 Dec; 31(12):1900-1907. PubMed ID: 36054458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
